
Gilead makes two senior promotions
pharmafile | January 30, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Gilead, andrew cheng
Gilead Sciences has promoted Dr Andrew Cheng to the position of executive vice president, HIV therapeutics and development operations, and Dr Taiyin Yang as executive VP of pharmaceutical development and manufacturing.
Cheng (pictured) and Yang will both join Gilead’s senior leadership committee. Cheng joined Gilead in 1999 and has led clinical development activities for the company’s development-stage programs in HIV/AIDS.
He reports to Dr Norbert Bischofberger, the firm’s executive VP of R&D and chief scientific officer. Prior to joining Gilead Cheng trained in internal medicine in the US at the University of California, Los Angeles.
Yang joined Gilead in 1993 and was promoted to senior VP in 2005. In her newly-expanded role she will be responsible for managing pharma development, analytical operations, laboratory information, quality assurance and manufacturing of both clinical and commercial drugs.
She also reports to Bischofberger and to John Milligan, Gilead’s president and chief operating officer. Prior to Gilead Yang was director of analytical chemistry at Syntex.
Bischofberger says: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products. They are experts in their respective fields and have helped build teams that are efficient and highly productive.”
Related Content

Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

Gilead shares phase 3 results from HIV prevention trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE …






